You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞銀窩輪》中移動好倉見顯著資金支持 看好中移動可留意中移牛證60801、中移認購23931
港股周四高開於25050點,其後走勢向下,失守25000點更跌至24650點水平,午後恆指慢慢回升,尾市時更倒升,最終全日升94點,收報24924點。 近日中移動(0941)受到市場關注,除了「回A」掛牌額外發行約5706.78萬股,額外集資32.86億元外;最新MSCI季度指數評估中,MSCI中國A股在岸指數將納入中移動A股,多方面的利好消息帶動港股的中移動股價屢有突破,截至周三,中移動收於高位57.9元,而周四中移動則略有回吐,下跌2.8%,收報56.3港元。根據瑞銀周四記錄,中移動相關牛證及認股證得到顯著資金支持,反映市場看好中移動的潛在升值能力。如希望以牛熊證作部署的投資者,看好中移動可留意中移牛證60801,收回價51港元,行使價50港元,22年11月到期,有效槓桿約10倍。如希望以認股證作部署的投資者,看好中移動,可留意中移認購23931,行使價62.93港元,22年8月到期,有效槓桿約7.9倍。 藥明生物(2269)及其關聯企業較早前遭美國納入「未經核實」實體名單,市場恐慌性拋售股份,最終周二股價挫22.8%,收報62.25港元;周三藥明復牌及至周四,藥明持續弱勢,周四股價再下跌5.4%,收報58.3港元,創近一年以來新低。由於藥明股價急跌,市面上大多數牛熊證都被收回或街貨量已屬偏高的情況(由於高街貨量的產品價格可能被推高於合理水平,建議投資者避開街貨量高的產品)。發行商近日都積極發行貼價的藥明牛熊證,將陸續於下周初上市,投資者可以密切留意新產品的推出。如希望以認股證作部署的投資者,看好藥明可留意藥明認購21096,行使價75.93港元,22年6月到期,有效槓桿約3.8倍。 更多窩輪牛熊資訊:瑞銀認股證牛熊證網站:http://www.ubs.com/hkwarrants 窩證教學及巿焦點況短片: https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber 謝宛彤 瑞銀亞洲股票衍生產品銷售部 本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~ 重要聲明: 以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account